Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

67.57
+1.792.72%
Volume:1.52M
Turnover:99.62M
Market Cap:3.30B
PE:-15.63
High:69.08
Open:64.50
Low:63.24
Close:65.78
52wk High:151.02
52wk Low:45.03
Shares:48.77M
Float Shares:29.72M
Volume Ratio:0.87
T/O Rate:5.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-257.82
PE(LYR):-17.83

Loading ...

Top Midday Gainers

MT Newswires Live
·
May 05

Celcuity rises 17.1%

TIPRANKS
·
May 04

Celcuity price target raised to $189 from $141 at Craig-Hallum

TIPRANKS
·
May 04

HC Wainwright Upgrades Celcuity to Buy From Neutral, Adjusts Price Target to $165 From $94

MT Newswires Live
·
May 04

Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results

Dow Jones
·
May 04

S&P 500 Futures Fall In Premarket Trading; Victory Capital, Black Hills Lag

Dow Jones
·
May 04

Guggenheim Keeps Their Buy Rating on Celcuity (CELC)

TIPRANKS
·
May 04

Celcuity Inc : H.c. Wainwright Raises to Buy From Neutral; Raises Target Price to $165 From $94

THOMSON REUTERS
·
May 04

Celcuity upgraded to Buy from Neutral at H.C. Wainwright

TIPRANKS
·
May 04

Celcuity price target raised to $160 from $150 at Citizens

TIPRANKS
·
May 04

Celcuity Is Maintained at Buy by Needham

Dow Jones
·
May 04

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Boston Scientific (BSX)

TIPRANKS
·
May 04

Celcuity Inc : Needham Raises Target Price to $155 From $122

THOMSON REUTERS
·
May 04

U.S. RESEARCH ROUNDUP- Alphabet, Colgate-Palmolive, Welltower

Reuters
·
May 04

Celcuity’s Phase 3 VIKTORIA-1 trial achieves primary endpoint

TIPRANKS
·
May 02

Celcuity says Phase 3 VIKTORIA-1 meets primary endpoint in PIK3CA-mutant breast cancer

Reuters
·
May 02

Celcuity Inc - to Submit Viktoria-1 Data to FDA as Supplemental Nda

THOMSON REUTERS
·
May 02

Celcuity's Phase 3 Viktoria-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in Pik3CA Mutant Cohort

THOMSON REUTERS
·
May 02

Celcuity Inc - FDA Grants Priority Review for Gedatolisib Nda With Pdufa Date July 17, 2026

THOMSON REUTERS
·
May 02

Celcuity Inc - Gedatolisib Regimens Show Manageable Safety Profiles With No New Safety Signals

THOMSON REUTERS
·
May 02